William Garvin, Shareholder in the firm's FDA & Biotechnology practice, comments on the impact of biosimilars, lower-priced copies of expensive biotechnology drugs, in Bloomberg BNA's article "Pfizer, J&J Antitrust Suit Is Next Big Pharma Fight." Pfizer Inc.'s suit alleging Johnson & Johnson stopped a biosimilar is the first lawsuit of its kind.